Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis;Moxifloxacino Como Terapia Alternativa o Aditiva Para el Tratamiento de la Tuberculosis Pulmonar

Annals of Pharmacotherapy

Volumn 45, Issue 11, 2011, Pages 1439-1444

  Fouad, Mohamed ^a,b   Gallagher, Jason C ^c  

^a TEMPLE UNIVERSITY   (United States)

^b Hospital pharmacist   (United States)

^c TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Fluoroquinolone; Moxifloxacin; Mycobacteria; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM ANALYSIS; SPUTUM CULTURE; SYSTEMATIC REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; PROSPECTIVE STUDIES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 80155167214     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q299     Document Type: Review

References (24)

1. World Health Organization. Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/index.html (accessed 2011 Jul 15).
2. World Health Organization. HIV/TB Facts 2011. http://www.who.int/hiv/topics/tb/hiv_tb_factsheet_june_2011.pdf (accessed 2011 Jul 14).
3. Centers for Disease Control and Prevention. Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2003;52:1-74.
4. Bozeman L, Burman W, Metchock B, Weiner M. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005;40:386-91.
5. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008(1):CD004795. DOI 10.1002/14651858.CD004795.pub3
6. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-9.
7. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-5.
8. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-9.
9. Angeby KA, Jureen P, Giske CG, et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010;65:946-52. DOI 10.1093/jac/dkq091
10. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-6.
11. Aber VR, Nunn AJ. Factors affecting relapse following short-course chemotherapy. Bull Int Union Against Tuberc 1978;53:260-4.
12. Mitchison D. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-3.
13. Tuberculosis Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons. Lancet 2002;360:528-34.
14. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the Medical British Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-79.
15. East African/British Medical Research Council. Controlled clinical trial of short-course (6-months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;1:1079-85.
16. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis 1978;118:219-28.
17. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-38. DOI 10.1164/rccm.200603-360OC
18. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial. Lancet 2009;373:1183-9.
19. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80. DOI 10.1164/rccm.200901-0078OC
20. Wang J-Y, Wang J-T, Tsai T-H, et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuber Lung Dis 2010;14:65-71.
21. Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. BMJ 2010;341:c4451. DOI 10.1136/bmj.c4451
22. Clinicaltrials.gov. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB). http://clinicaltrials.gov/ct2/show/NCT00864383?term=moxifloxacin+and +tuberculosis&rank=3 (accessed 2011 Apr 15).
23. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004;190:1642-51.
24. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011;erj01766-2010. DOI 10.1183/09031936.00176610